1158 related articles for article (PubMed ID: 29785101)
1. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.
Mannino DM; Clerisme-Beaty EM; Franceschina J; Ting N; Leidy NK
Int J Chron Obstruct Pulmon Dis; 2018; 13():1515-1525. PubMed ID: 29785101
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
Rhee CK; Park HY; Park JW; Lee JH; Kim TH; Lee SW; Jung JY; Kim S; Hwang YI; Jung KS
Trials; 2017 Feb; 18(1):80. PubMed ID: 28228162
[TBL] [Abstract][Full Text] [Related]
3. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
5. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
[TBL] [Abstract][Full Text] [Related]
7. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
Marin JM; Beeh KM; Clemens A; Castellani W; Schaper L; Saralaya D; Gunstone A; Casamor R; Kostikas K; Aalamian-Mattheis M
Int J Chron Obstruct Pulmon Dis; 2016; 11():1425-34. PubMed ID: 27418815
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
[TBL] [Abstract][Full Text] [Related]
10. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
Sethi S; Kerwin E; Watz H; Ferguson GT; Mroz RM; Segarra R; Molins E; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2019; 14():667-682. PubMed ID: 30962681
[TBL] [Abstract][Full Text] [Related]
11. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
[TBL] [Abstract][Full Text] [Related]
12. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
Kardos P; Hagedorn-Peinz I
Int J Chron Obstruct Pulmon Dis; 2018; 13():69-77. PubMed ID: 29317812
[TBL] [Abstract][Full Text] [Related]
13. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods.
Kwak MS; Kim E; Jang EJ; Kim HJ; Lee CH
Int J Chron Obstruct Pulmon Dis; 2015; 10():2365-76. PubMed ID: 26604734
[TBL] [Abstract][Full Text] [Related]
15. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD.
Singh D; D'Urzo AD; Donohue JF; Kerwin EM; Molins E; Chuecos F; Ribera A; Jarreta D
Int J Chron Obstruct Pulmon Dis; 2019; 14():2835-2848. PubMed ID: 31827323
[TBL] [Abstract][Full Text] [Related]
16. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
Anzueto AR; Vogelmeier CF; Kostikas K; Mezzi K; Fucile S; Bader G; Shen S; Banerji D; Fogel R
Int J Chron Obstruct Pulmon Dis; 2017; 12():1325-1337. PubMed ID: 28496316
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
Saito T; Takeda A; Hashimoto K; Kobayashi A; Hayamizu T; Hagan GW
Int J Chron Obstruct Pulmon Dis; 2015; 10():2393-404. PubMed ID: 26604737
[TBL] [Abstract][Full Text] [Related]
18. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
Maltais F; O'Donnell D; Gáldiz Iturri JB; Kirsten AM; Singh D; Hamilton A; Tetzlaff K; Zhao Y; Casaburi R
Ther Adv Respir Dis; 2018; 12():1753465818755091. PubMed ID: 29439648
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study.
Fujimoto K; Yamazaki H; Ura M; Kitaguchi Y
Int J Chron Obstruct Pulmon Dis; 2017; 12():3195-3201. PubMed ID: 29138547
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
D'Urzo AD; Singh D; Donohue JF; Kerwin EM; Ribera A; Molins E; Chuecos F; Jarreta D; Gil EG
Int J Chron Obstruct Pulmon Dis; 2019; 14():479-491. PubMed ID: 30880938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]